Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS

Documenti analoghi

• Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients
  di: Zinzani, Pier Luigi, et al.
  Pubblicazione: (2015)
• Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients
  di: Gandolfi, Letizia, et al.
  Pubblicazione: (2016)
• First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi
  di: Broccoli, A., et al.
  Pubblicazione: (2019)
• Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials
  di: Zinzani, Pier Luigi, et al.
  Pubblicazione: (2013)
• Brentuximab vedotin followed by ABVD +/− radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study
  di: Federico, Massimo, et al.
  Pubblicazione: (2016)